Skip to content

About CLTI
Contact
International

Technology
- Products
- Instructions for Use
Healthcare Professionals
Clinical Evidence
U.S. Clinical Trial
Reimbursement Resources
Patients
Company
- Clinical Advisors
- News
- Media
- Articles
- Careers

Jun 6 2017

Midterm Outcomes From a Pilot Study
of Percutaneous Deep Vein Arterialization
for the Treatment of No-Option
Critical Limb Ischemia

View the article.

LimFlow Expands Senior Management Team and Opens Silicon Valley Office LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

Related Posts

FDA APPROVES LIMFLOW SYSTEM IN PATIENTS WITH CHRONIC LIMB-THREATENING ISCHEMIA AND NO SUITABLE ENDOVASCULAR OR SURGICAL REVASCULARIZATION OPTIONS

LANDMARK NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION REPORTS POSITIVE RESULTS FROM PROMISE II PIVOTAL TRIAL SHOWING THAT LIMFLOW SYSTEM SAVES MOST PATIENTS WITH END-STAGE PERIPHERAL ARTERY DISEASE FROM MAJOR AMPUTATION

LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS

Recent Posts

FDA APPROVES LIMFLOW SYSTEM IN PATIENTS WITH CHRONIC LIMB-THREATENING ISCHEMIA AND NO SUITABLE ENDOVASCULAR OR SURGICAL REVASCULARIZATION OPTIONS
LANDMARK NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION REPORTS POSITIVE RESULTS FROM PROMISE II PIVOTAL TRIAL SHOWING THAT LIMFLOW SYSTEM SAVES MOST PATIENTS WITH END-STAGE PERIPHERAL ARTERY DISEASE FROM MAJOR AMPUTATION
LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS
LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT
LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

The LimFlow System is approved for sale in markets regulated by the CE Mark.

©2020-present LimFlow SA | Site designed by The Deciding Factor, Inc.